JCAR014
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for JCAR014, covering 2022-08-24 to 2022-08-24. Get the full timeline:
Most recent: Clinical Trial Update: JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]